15 results
Pharmacologic treatment algorithms by Global Initiative for Chronic Obstructive Lung Disease grade. Highlighted boxes and arrows
Pharmacologic treatment ... indicate preferred treatment ... long-acting β2-agonist; ICS ... #Management #Pulmonary ... GOLD2017 #LAMA #LABA #ICS
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Triggers: ATRA treatment ... 5 or elevated Cr ... - pulmonary opacities ... organ dysfuxtion, ICU ... diagnosis #management #hematology
Medical Treatment Algorithm for Chronic Obstructive Pulmonary Disease
Initial medical treatment of chronic obstructive pulmonary disease (COPD)
Chronic Obstructive Pulmonary ... chronic obstructive pulmonary ... of expiration; ICS ... LAMA #SABA #SAMA #ICS ... #Pharmacology
Stress Ulcer Prophylaxis

Stress ulcerations are common in ICU patients and may lead to hemorrhage if not
are common in ICU ... ulceration or treatment ... Risk Factors • Clinical ... #criticalcare #pharmacology
TRALI vs TACO - Transfusion Reactions
TRALI:
 • Epidemiology: 0.1% of transfused patientsl
 • Risk factors: Critical
Risk factors: Critical ... : 33% • Treatment ... fluid balance, and CXR ... with pulmonary ... Transfusion #Reactions #hematology
Daliresp (Roflumilast) 
Indication: Reduce risk of COPD exacerbations 
Drug Class: Selective Phosphodiesterase-4 (PDE4) Inhibitor 
GOLD 2019
Therapy (LAMA/LABA/ICS ... recommendations for the treatment ... low, adding an ICS ... won’t have any clinical ... #Indications #Pharmacology
Hemophagocytic Lymphohistiocytosis (HLH)
Pathophysiology: Triggering factor (infection,...)→Activation of CD8 T cells (IFN-y) → Excessive activation of macrophages
accumulation of clinical ... Assessment • Clinical ... Unknown cause Treatment ... of emergency, ICU ... #summary #rheumatology
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
with presence of pulmonary ... & Dry) is the treatment ... & Dry” is the treatment ... #criticalcare #icu ... #clinical #pharmacology
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
characteristic features Clinical ... staining, NAA (PCR ... and Culture • CXR ... Tuberculosis Treatment ... disease • Check CXR
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
characteristic features Clinical ... staining, NAA (PCR ... and Culture • CXR ... Tuberculosis Treatment ... disease • Check CXR